The FDA handed Gossamer Bio, a biotech company, a partial clinical hold after two patients died in its BTK inhibitor trial, EndPoints News reported April 3.
Read the full post on Becker's Hospital Review - Healthcare News
FDA stops cancer drug trial after two patient deaths
